[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-001", "question": "A 26-year-old G2P1 at 30 weeks' gestation presents with new-onset severe occipital headache, visual scotomata, and right upper quadrant pain. BP is 168/108 mmHg, HR 88, reflexes 3+ with 1-2 beats of clonus. Fetal heart tracing is category I. Labs: platelets 86,000/µL, AST 145 U/L, ALT 162 U/L, creatinine 0.9 mg/dL, urine protein/creatinine ratio 0.5. She received 10 mg IV hydralazine in triage 20 minutes ago; current BP is 162/104 mmHg. She desires future fertility and vaginal delivery if safe. What is the most appropriate NEXT step in management?", "options": ["Administer IV labetalol now and plan for induction of labor at 34 weeks", "Initiate magnesium sulfate and proceed with immediate induction of labor", "Initiate magnesium sulfate and administer betamethasone; plan delivery within 24 hours", "Administer additional IV hydralazine and observe; defer delivery until 34 weeks if blood pressure controlled", "Start oral labetalol and discharge with close outpatient follow-up and twice-weekly NSTs"], "answer": "C", "answer_index": 2, "explanation": "She has preeclampsia with severe features and evolving HELLP (thrombocytopenia, RUQ pain, transaminitis) at 30 weeks. For severe features <34 weeks, optimal care is magnesium, corticosteroids, and expedited delivery within 24 hours at a tertiary center, not expectant management. Immediate induction ignores steroid window and maternal stability; outpatient or prolonged expectant management is unsafe given platelets <100,000 and worsening symptoms.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 26-year-old G2P1 at 30 weeks with severe preeclampsia/evolving HELLP syndrome: severe-range BP (168/108→162/104 despite hydralazine), thrombocytopenia (86,000/µL), elevated transaminases (AST 145, ALT 162), RUQ pain, visual scotomata, severe headache, and hyperreflexia with clonus. Key discriminating findings: <34 weeks gestation with severe features requiring delivery, but maternal condition stable enough to allow brief delay for corticosteroids. Option C correctly initiates magnesium sulfate (seizure prophylaxis mandatory for severe features), administers betamethasone (fetal lung maturity for 30-week delivery), and plans delivery within 24 hours (balancing maternal safety with steroid benefit window). Option A delays to 34 weeks—unsafe with HELLP evolving. Option B immediate induction forgoes critical steroid window when 24-hour delay is safe. Option D expectant management to 34 weeks contradicts guidelines for severe features with HELLP. Option E outpatient management is dangerous with platelets <100,000 and severe symptoms. No logical flaws; stem provides sufficient detail. Medical accuracy: fully consistent with ACOG guidelines for preeclampsia with severe features at <34 weeks. Minimal fix: none needed; item is valid and accurate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 26-year-old G2P1 at 30 weeks with severe preeclampsia/evolving HELLP syndrome: severe-range BP (168/108→162/104 despite hydralazine), thrombocytopenia (86,000/µL), elevated transaminases (AST 145, ALT 162), RUQ pain, visual scotomata, severe headache, and hyperreflexia with clonus. Key discriminating findings: <34 weeks gestation with severe features requiring delivery, but maternal condition stable enough to allow brief delay for corticosteroids. Option C correctly initiates magnesium sulfate (seizure prophylaxis mandatory for severe features), administers betamethasone (fetal lung maturity for 30-week delivery), and plans delivery within 24 hours (balancing maternal safety with steroid benefit window). Option A delays to 34 weeks—unsafe with HELLP evolving. Option B immediate induction forgoes critical steroid window when 24-hour delay is safe. Option D expectant management to 34 weeks contradicts guidelines for severe features with HELLP. Option E outpatient management is dangerous with platelets <100,000 and severe symptoms. No logical flaws; stem provides sufficient detail. Medical accuracy: fully consistent with ACOG guidelines for preeclampsia with severe features at <34 weeks. Minimal fix: none needed; item is valid and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-002", "question": "A 58-year-old man with ischemic cardiomyopathy (LVEF 20%), CRT-D in place, and NYHA class III symptoms despite optimal GDMT (sacubitril/valsartan, carvedilol, spironolactone, empagliflozin, loop diuretic) presents with weight gain and dyspnea. BP 104/66 mmHg, HR 72 (biventricular paced), JVP 12 cm, bibasilar crackles, moderate ascites, no peripheral edema. Labs: Na 130 mEq/L, K 4.4, creatinine 1.8 (baseline 1.3), NT-proBNP 12,000 pg/mL. Echo: LVEF 20%, severe functional MR, normal RV size, mildly reduced RV function, PASP 55 mmHg. Right heart cath: RAP 18 mmHg, PCWP 32 mmHg, CI 1.7 L/min/m², SVR 2100 dyn·s/cm⁵. After IV diuresis, he remains hypotensive with CI 1.6. He is INTERMACS profile 4. What is the best definitive next step?", "options": ["Add continuous IV milrinone as palliative inotropic therapy without advanced therapies", "Refer for urgent isolated cardiac transplantation listing status 2 without LVAD bridge", "Evaluate for transcatheter edge-to-edge repair (TEER) of the mitral valve to reduce MR", "Refer for durable LVAD implantation as bridge to transplant or destination therapy", "Implant a percutaneous Impella device as bridge to decision in the ICU"], "answer": "D", "answer_index": 3, "explanation": "He has advanced, stage D HFrEF with persistent low-output symptoms, high filling pressures, and INTERMACS profile 4, making him appropriate for durable LVAD as bridge to transplant or destination. Isolated transplant without LVAD is not ideal given instability; TEER is for less advanced, stable patients. Chronic inotropes or short-term MCS alone are not definitive strategies in a transplant/LVAD candidate.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 58-year-old man with advanced HFrEF (LVEF 20%), INTERMACS profile 4, persistent low cardiac output (CI 1.6-1.7), elevated filling pressures (PCWP 32, RAP 18), and refractory symptoms despite optimal GDMT and CRT-D. Key discriminating findings: INTERMACS 4 (ambulatory but frequent symptoms), hemodynamic compromise with CI <2.0, worsening renal function, hyponatremia, and failure to improve after diuresis. The clinical problem is identifying definitive therapy for advanced heart failure in a potential transplant candidate. Option D (durable LVAD) is the appropriate definitive strategy for INTERMACS 3-4 patients who are transplant candidates or destination therapy candidates, providing long-term mechanical support. Option A (palliative milrinone) is not definitive and increases mortality risk. Option B (urgent transplant listing without bridge) is inappropriate given hemodynamic instability and INTERMACS 4 status. Option C (TEER) is for stable, less advanced patients with primary MR, not severe functional MR in cardiogenic shock. Option E (Impella) provides only temporary support, not definitive therapy. The item is medically accurate, reflecting current advanced heart failure management guidelines. No logical flaws or missing critical details. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 58-year-old man with advanced HFrEF (LVEF 20%), INTERMACS profile 4, persistent low cardiac output (CI 1.6-1.7), elevated filling pressures (PCWP 32, RAP 18), and refractory symptoms despite optimal GDMT and CRT-D. Key discriminating findings: INTERMACS 4 (ambulatory but frequent symptoms), hemodynamic compromise with CI <2.0, worsening renal function, hyponatremia, and failure to improve after diuresis. The clinical problem is identifying definitive therapy for advanced heart failure in a potential transplant candidate. Option D (durable LVAD) is the appropriate definitive strategy for INTERMACS 3-4 patients who are transplant candidates or destination therapy candidates, providing long-term mechanical support. Option A (palliative milrinone) is not definitive and increases mortality risk. Option B (urgent transplant listing without bridge) is inappropriate given hemodynamic instability and INTERMACS 4 status. Option C (TEER) is for stable, less advanced patients with primary MR, not severe functional MR in cardiogenic shock. Option E (Impella) provides only temporary support, not definitive therapy. The item is medically accurate, reflecting current advanced heart failure management guidelines. No logical flaws or missing critical details. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-003", "question": "A previously healthy 4-year-old boy presents with 10 days of fever to 39.5°C, conjunctival injection without exudate, cracked lips, polymorphous trunk rash, edema and erythema of hands and feet, and cervical lymphadenopathy. Symptoms partially improved after ibuprofen but recur when stopped. Day-10 echocardiogram: diffuse coronary artery ectasia with z-scores 2.3-2.7, mild LV dysfunction (EF 50%), and small pericardial effusion. Labs: WBC 14,000/µL, platelets 520,000/µL, CRP 10 mg/dL, ESR 80 mm/hr, ALT mildly elevated, sterile pyuria. COVID serology and respiratory viral panel are negative. He has not yet received IVIG. What is the most appropriate initial treatment strategy now?", "options": ["Single dose IVIG 2 g/kg plus high-dose aspirin only", "IVIG 2 g/kg, high-dose aspirin, and a single dose of IV methylprednisolone 30 mg/kg", "IVIG 2 g/kg, low-dose aspirin, and infliximab 5 mg/kg", "IVIG 2 g/kg, high-dose aspirin, and anakinra 2 mg/kg/day", "High-dose aspirin alone because presentation is after day 10 of illness"], "answer": "B", "answer_index": 1, "explanation": "He has classic Kawasaki disease with coronary changes and delayed presentation, which confers high risk of IVIG resistance and coronary progression. Current risk-adapted approaches favor adjunctive corticosteroids with IVIG in high-risk patients (coronary involvement and very elevated inflammatory markers), even after day 10. Aspirin monotherapy is inadequate; biologics are reserved for IVIG-resistant disease.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 4-year-old with classic Kawasaki disease (KD): prolonged fever ≥5 days, bilateral conjunctival injection, oral changes (cracked lips), polymorphous rash, extremity changes (edema/erythema), and cervical lymphadenopathy—meeting ≥5 of 5 principal criteria. Critical discriminating findings include day-10 presentation with established coronary artery ectasia (z-scores 2.3-2.7), LV dysfunction (EF 50%), pericardial effusion, and markedly elevated inflammatory markers (CRP 10 mg/dL, ESR 80 mm/hr, thrombocytosis 520k). These features define high-risk KD with coronary involvement and predict IVIG resistance. Option B (IVIG 2 g/kg + high-dose aspirin + IV methylprednisolone 30 mg/kg) aligns with current risk-stratified treatment paradigms: adjunctive corticosteroids are recommended for high-risk patients with coronary abnormalities at presentation to reduce IVIG resistance and improve coronary outcomes. Option A lacks intensification for high-risk disease. Option C uses low-dose aspirin (incorrect in acute phase) and infliximab (reserved for IVIG-refractory cases). Option D employs anakinra without established first-line role. Option E (aspirin monotherapy) is dangerous—IVIG remains indicated even after day 10 when coronary changes present. Medical accuracy is excellent; the item reflects contemporary AHA/expert consensus on risk-adapted KD management. No logical flaws or ambiguity exist.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 4-year-old with classic Kawasaki disease (KD): prolonged fever ≥5 days, bilateral conjunctival injection, oral changes (cracked lips), polymorphous rash, extremity changes (edema/erythema), and cervical lymphadenopathy—meeting ≥5 of 5 principal criteria. Critical discriminating findings include day-10 presentation with established coronary artery ectasia (z-scores 2.3-2.7), LV dysfunction (EF 50%), pericardial effusion, and markedly elevated inflammatory markers (CRP 10 mg/dL, ESR 80 mm/hr, thrombocytosis 520k). These features define high-risk KD with coronary involvement and predict IVIG resistance. Option B (IVIG 2 g/kg + high-dose aspirin + IV methylprednisolone 30 mg/kg) aligns with current risk-stratified treatment paradigms: adjunctive corticosteroids are recommended for high-risk patients with coronary abnormalities at presentation to reduce IVIG resistance and improve coronary outcomes. Option A lacks intensification for high-risk disease. Option C uses low-dose aspirin (incorrect in acute phase) and infliximab (reserved for IVIG-refractory cases). Option D employs anakinra without established first-line role. Option E (aspirin monotherapy) is dangerous—IVIG remains indicated even after day 10 when coronary changes present. Medical accuracy is excellent; the item reflects contemporary AHA/expert consensus on risk-adapted KD management. No logical flaws or ambiguity exist.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-004", "question": "A 32-year-old woman with mixed connective tissue disease (U1-RNP positive) on mycophenolate mofetil and low-dose prednisone presents with 3 months of progressive exertional dyspnea and near-syncope. Exam: loud P2, right ventricular heave, no crackles, no edema. HR 94, BP 108/68 mmHg, O2 sat 95% on room air. CT chest: no interstitial lung disease, no PE. TTE: normal LV, moderately dilated RV with reduced function, estimated PASP 75 mmHg, no shunt. Right heart cath: mPAP 46 mmHg, PAOP 9 mmHg, CI 2.0 L/min/m², PVR 9 Wood units. Autoantibodies: strong anti-U1-RNP, negative anti-Scl-70. She desires pregnancy within 1-2 years. What is the most appropriate initial advanced therapy strategy for her pulmonary hypertension?", "options": ["Start amlodipine after acute vasoreactivity testing, then titrate based on BP", "Initiate dual oral therapy with ambrisentan and tadalafil", "Initiate triple therapy including IV epoprostenol plus an endothelin receptor antagonist and a PDE-5 inhibitor", "Start inhaled treprostinil monotherapy and observe functional response", "Use riociguat monotherapy given connective tissue disease-associated PAH"], "answer": "C", "answer_index": 2, "explanation": "She has high-risk WHO group 1 CTD-associated PAH (RV dysfunction, mPAP 46, CI 2.0, PVR 9) and plans pregnancy (a major risk), warranting aggressive up-front therapy. Modern guidelines recommend initial triple therapy with parenteral prostacyclin in high-risk PAH patients. CCBs are only for acute vasoreactivity responders; dual or single oral agents are insufficient for this profile.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 32-year-old woman with MCTD-associated pulmonary arterial hypertension (PAH) presenting with high-risk features: RV dysfunction on echo, mPAP 46 mmHg, critically low cardiac index (2.0 L/min/m²), elevated PVR (9 Wood units), WHO functional class III symptoms (near-syncope, progressive dyspnea), and planned pregnancy within 1-2 years. Key discriminating findings: hemodynamic confirmation of precapillary PH (PAOP 9, elevated PVR), CTD-associated PAH (WHO Group 1), and multiple high-risk markers. The keyed answer (C: triple therapy with IV epoprostenol plus ERA and PDE-5i) aligns with current ESC/ERS guidelines recommending initial combination therapy including parenteral prostacyclin for high-risk PAH patients. Option A is incorrect (vasoreactivity testing rarely positive in CTD-PAH; CCBs contraindicated without positive response). Option B (dual oral therapy) is insufficient for high-risk disease. Options D and E (monotherapy) are inadequate given risk stratification. The pregnancy consideration further supports aggressive therapy. Medical accuracy is excellent, reflecting 2022 ESC/ERS PAH guidelines. No logical flaws; stem provides sufficient discriminating data. Minimal fix: None needed; item is well-constructed and defensible.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 32-year-old woman with MCTD-associated pulmonary arterial hypertension (PAH) presenting with high-risk features: RV dysfunction on echo, mPAP 46 mmHg, critically low cardiac index (2.0 L/min/m²), elevated PVR (9 Wood units), WHO functional class III symptoms (near-syncope, progressive dyspnea), and planned pregnancy within 1-2 years. Key discriminating findings: hemodynamic confirmation of precapillary PH (PAOP 9, elevated PVR), CTD-associated PAH (WHO Group 1), and multiple high-risk markers. The keyed answer (C: triple therapy with IV epoprostenol plus ERA and PDE-5i) aligns with current ESC/ERS guidelines recommending initial combination therapy including parenteral prostacyclin for high-risk PAH patients. Option A is incorrect (vasoreactivity testing rarely positive in CTD-PAH; CCBs contraindicated without positive response). Option B (dual oral therapy) is insufficient for high-risk disease. Options D and E (monotherapy) are inadequate given risk stratification. The pregnancy consideration further supports aggressive therapy. Medical accuracy is excellent, reflecting 2022 ESC/ERS PAH guidelines. No logical flaws; stem provides sufficient discriminating data. Minimal fix: None needed; item is well-constructed and defensible.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-005", "question": "A 24-year-old primigravida at 11 weeks presents with severe nausea, non-bloody emesis 10-15 times daily, 4-kg weight loss, orthostatic tachycardia, and inability to keep down oral medications despite pyridoxine/doxylamine and rectal promethazine. She has ketonuria, Na 131 mEq/L, K 2.9 mEq/L, bicarbonate 19 mEq/L, ALT 78 U/L, AST 65 U/L, normal lipase and thyroid function. Ultrasound: single viable intrauterine pregnancy. She requests to avoid hospitalization if possible and is anxious about teratogenic risk. What is the most appropriate next-step pharmacologic management in addition to IV fluids and electrolyte repletion?", "options": ["Start oral ondansetron and allow discharge with close outpatient follow-up", "Begin continuous subcutaneous metoclopramide infusion as an outpatient", "Administer IV ondansetron and admit for parenteral nutrition via PICC line", "Start transdermal scopolamine and oral mirtazapine", "Administer IV chlorpromazine now and transition to scheduled IV ondansetron or metoclopramide in the hospital"], "answer": "E", "answer_index": 4, "explanation": "She has hyperemesis gravidarum with significant volume depletion and electrolyte derangements, requiring inpatient care and parenteral antiemetics. Phenothiazines (e.g., IV chlorpromazine) followed by scheduled IV ondansetron or metoclopramide are evidence-based for refractory hyperemesis. Outpatient oral or SC regimens are inappropriate given inability to tolerate PO; TPN is reserved for failure of intensive antiemetic therapy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes severe hyperemesis gravidarum with dehydration (4-kg weight loss, orthostatic tachycardia), ketonuria, hyponatremia (131), hypokalemia (2.9), metabolic acidosis (bicarbonate 19), and transaminitis—all indicating need for hospitalization despite patient preference. Key discriminating findings: failed outpatient oral/rectal antiemetics, inability to tolerate PO medications, significant electrolyte derangements requiring IV correction. The clinical problem asks for next pharmacologic step beyond IV fluids/electrolytes in a patient requiring admission. Option E (IV chlorpromazine transitioning to scheduled IV ondansetron/metoclopramide) is appropriate for refractory hyperemesis requiring inpatient parenteral therapy. Option A is contraindicated—patient cannot tolerate oral medications and has severe dehydration requiring admission. Option B (subcutaneous metoclopramide outpatient) inadequately addresses severe dehydration/electrolyte abnormalities. Option C jumps to TPN prematurely before intensive antiemetic trial. Option D (scopolamine/mirtazapine) uses agents with limited evidence and includes oral medication the patient cannot tolerate. The item correctly identifies that phenothiazines are evidence-based for refractory hyperemesis and appropriately sequences care (immediate IV antiemetic, then scheduled regimen). Medical accuracy is sound regarding hyperemesis management and admission criteria. No logical flaws or ambiguity present.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes severe hyperemesis gravidarum with dehydration (4-kg weight loss, orthostatic tachycardia), ketonuria, hyponatremia (131), hypokalemia (2.9), metabolic acidosis (bicarbonate 19), and transaminitis—all indicating need for hospitalization despite patient preference. Key discriminating findings: failed outpatient oral/rectal antiemetics, inability to tolerate PO medications, significant electrolyte derangements requiring IV correction. The clinical problem asks for next pharmacologic step beyond IV fluids/electrolytes in a patient requiring admission. Option E (IV chlorpromazine transitioning to scheduled IV ondansetron/metoclopramide) is appropriate for refractory hyperemesis requiring inpatient parenteral therapy. Option A is contraindicated—patient cannot tolerate oral medications and has severe dehydration requiring admission. Option B (subcutaneous metoclopramide outpatient) inadequately addresses severe dehydration/electrolyte abnormalities. Option C jumps to TPN prematurely before intensive antiemetic trial. Option D (scopolamine/mirtazapine) uses agents with limited evidence and includes oral medication the patient cannot tolerate. The item correctly identifies that phenothiazines are evidence-based for refractory hyperemesis and appropriately sequences care (immediate IV antiemetic, then scheduled regimen). Medical accuracy is sound regarding hyperemesis management and admission criteria. No logical flaws or ambiguity present.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-006", "question": "A 17-year-old previously healthy boy is admitted to the ICU with septic shock due to meningococcemia, requiring norepinephrine and mechanical ventilation. On day 4, BP stabilizes and pressors are stopped. Over the next 24 hours, he develops rapidly worsening hypoxemia with PaO2/FiO2 ratio 90, diffuse bilateral infiltrates, and new hemoptysis. Hb drops from 11 to 8 g/dL without obvious bleeding. Platelets are 220,000/µL, PT/INR normal, PTT normal, fibrinogen 400 mg/dL. Urinalysis: 3+ blood, 2+ protein, many dysmorphic RBCs. Creatinine rises from 0.8 to 2.1 mg/dL. ANA negative, ANCA panel negative, complements normal. Bronchoscopy shows diffuse alveolar hemorrhage; cultures pending. What is the most appropriate next step in management?", "options": ["High-dose IV methylprednisolone and IV cyclophosphamide for presumed ANCA-negative pulmonary-renal vasculitis", "Plasmapheresis plus pulse steroids for suspected anti-GBM disease despite negative serology", "Supportive care only, assuming septic coagulopathy-related lung injury", "Kidney biopsy as soon as feasible to guide immunosuppression decisions", "Start rituximab and prednisone for suspected immune-complex GN related to sepsis"], "answer": "D", "answer_index": 3, "explanation": "He has a pulmonary-renal syndrome with DAH and GN but negative ANCA/anti-GBM serologies and preserved platelets/coagulation, making pure septic DIC unlikely. In this critically ill patient, tissue diagnosis is essential before committing to aggressive immunosuppression, especially with negative serologies. Early kidney biopsy best clarifies the etiology; empiric cytotoxic therapy or plasmapheresis without diagnosis carries high risk and may be inappropriate if the lesion is infection-related.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. The vignette describes a 17-year-old with meningococcemia who develops pulmonary-renal syndrome (diffuse alveolar hemorrhage + glomerulonephritis with dysmorphic RBCs, proteinuria, rising creatinine) on day 5 of illness. Key discriminating findings: (1) DAH with hemoptysis and PaO2/FiO2=90, (2) glomerulonephritis (dysmorphic RBCs, proteinuria, Cr 0.8→2.1), (3) negative ANCA/ANA/anti-GBM serologies, (4) normal coagulation studies and platelets ruling out DIC, (5) recent severe infection. The differential includes ANCA-negative vasculitis, anti-GBM disease with false-negative serology, infection-associated GN, or post-infectious immune complex disease. Option D (kidney biopsy) is the single best answer because: tissue diagnosis is essential before committing to aggressive immunosuppression in a critically ill septic patient with negative serologies; biopsy can distinguish vasculitis, anti-GBM, immune-complex GN, or infection-related pathology. Options A/B/E involve empiric immunosuppression without tissue diagnosis—dangerous if infection-driven. Option C ignores the clear GN and preserved coagulation. The item is logically valid with appropriate clinical reasoning. Medical accuracy is high; reflects standard practice requiring histologic confirmation before cytotoxic therapy in ambiguous pulmonary-renal syndromes. Minimal fix: none needed.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 17-year-old with meningococcemia who develops pulmonary-renal syndrome (diffuse alveolar hemorrhage + glomerulonephritis with dysmorphic RBCs, proteinuria, rising creatinine) on day 5 of illness. Key discriminating findings: (1) DAH with hemoptysis and PaO2/FiO2=90, (2) glomerulonephritis (dysmorphic RBCs, proteinuria, Cr 0.8→2.1), (3) negative ANCA/ANA/anti-GBM serologies, (4) normal coagulation studies and platelets ruling out DIC, (5) recent severe infection. The differential includes ANCA-negative vasculitis, anti-GBM disease with false-negative serology, infection-associated GN, or post-infectious immune complex disease. Option D (kidney biopsy) is the single best answer because: tissue diagnosis is essential before committing to aggressive immunosuppression in a critically ill septic patient with negative serologies; biopsy can distinguish vasculitis, anti-GBM, immune-complex GN, or infection-related pathology. Options A/B/E involve empiric immunosuppression without tissue diagnosis—dangerous if infection-driven. Option C ignores the clear GN and preserved coagulation. The item is logically valid with appropriate clinical reasoning. Medical accuracy is high; reflects standard practice requiring histologic confirmation before cytotoxic therapy in ambiguous pulmonary-renal syndromes. Minimal fix: none needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-007", "question": "A 6-week-old full-term girl presents with poor feeding, tachypnea, and sweating with feeds. Weight is at the 3rd percentile (previously 40th). Vitals: HR 180, RR 60, BP 70/40 mmHg in all extremities, O2 sat 96% RA. Exam: hepatomegaly, gallop rhythm, 2/6 holosystolic murmur at apex radiating to axilla, no differential pulses. CXR: cardiomegaly, pulmonary overcirculation. Echo: dilated LV with EF 20%, moderate MR, normal coronaries, no coarctation or structural shunt, normal RV function. ECG: sinus tachycardia. Blood and viral studies pending. After starting IV milrinone and diuretics, she stabilizes. What is the MOST appropriate next step in definitive management planning?", "options": ["Discontinue inotropes as soon as EF improves above 35% and transition to oral heart failure therapy only", "Urgently list for heart transplant as status 1A given high mortality of infantile dilated cardiomyopathy", "Begin high-dose IVIG for presumed viral myocarditis and defer consideration of mechanical support", "Evaluate for durable LVAD candidacy as bridge to transplant or recovery", "Schedule elective mitral valve repair to reduce regurgitation and improve LV function"], "answer": "D", "answer_index": 3, "explanation": "She has severe idiopathic/viral dilated cardiomyopathy with EF 20% and inotrope dependence, placing her at high risk of deterioration. Early evaluation for durable LVAD as bridge to transplant or recovery is recommended in infants with advanced heart failure who respond incompletely to medical therapy. Immediate transplant listing without MCS may be risky given wait times; valve surgery will not address primary LV dysfunction; IVIG alone is insufficient as definitive strategy.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 6-week-old with severe dilated cardiomyopathy (EF 20%) who stabilizes on milrinone and diuretics, asking for the \\\"MOST appropriate next step in definitive management planning.\\\" Key discriminating findings: severe LV dysfunction (EF 20%), inotrope-dependent stabilization, normal coronaries, pending viral studies. The critical missing detail is the degree and duration of inotrope dependence after stabilization. If she weans off inotropes successfully, oral therapy (A) becomes appropriate. If she remains inotrope-dependent despite stabilization, LVAD evaluation (D) or transplant listing (B) become more urgent. The stem states \\\"she stabilizes\\\" but doesn't specify whether this means inotrope-independence or merely hemodynamic improvement while still requiring IV support. Option D (LVAD evaluation) assumes persistent high-risk features warranting mechanical support consideration. Option B (transplant listing) is also defensible for severe infantile DCM with poor prognosis. The distinction between \\\"evaluation for LVAD\\\" versus \\\"listing for transplant\\\" as the immediate next step requires knowing the patient's trajectory post-stabilization. Medical accuracy: The management approach is generally sound, though LVAD use in 6-week-old infants faces significant technical limitations. Minimal fix: Specify \\\"remains inotrope-dependent after 48-72 hours\\\" to justify advanced therapies over medical optimization.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) leading to M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 6-week-old with severe dilated cardiomyopathy (EF 20%) who stabilizes on milrinone and diuretics, asking for the \"MOST appropriate next step in definitive management planning.\" Key discriminating findings: severe LV dysfunction (EF 20%), inotrope-dependent stabilization, normal coronaries, pending viral studies. The critical missing detail is the degree and duration of inotrope dependence after stabilization. If she weans off inotropes successfully, oral therapy (A) becomes appropriate. If she remains inotrope-dependent despite stabilization, LVAD evaluation (D) or transplant listing (B) become more urgent. The stem states \"she stabilizes\" but doesn't specify whether this means inotrope-independence or merely hemodynamic improvement while still requiring IV support. Option D (LVAD evaluation) assumes persistent high-risk features warranting mechanical support consideration. Option B (transplant listing) is also defensible for severe infantile DCM with poor prognosis. The distinction between \"evaluation for LVAD\" versus \"listing for transplant\" as the immediate next step requires knowing the patient's trajectory post-stabilization. Medical accuracy: The management approach is generally sound, though LVAD use in 6-week-old infants faces significant technical limitations. Minimal fix: Specify \"remains inotrope-dependent after 48-72 hours\" to justify advanced therapies over medical optimization.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-008", "question": "A 29-year-old woman at 36+1 weeks with known SLE (class IV lupus nephritis in remission on azathioprine and hydroxychloroquine) presents with 3 days of severe frontal headache, visual blurring, and increasing lower extremity edema. BP 164/102 mmHg (baseline 110/70), HR 92. Labs: platelets 185,000/µL, AST 40 U/L, ALT 35 U/L, creatinine 1.3 mg/dL (baseline 1.1), urine protein/creatinine ratio 2.2 (baseline 1.8), C3 and C4 low, anti-dsDNA titer increased from 1:80 to 1:320, urinalysis with active sediment (RBC casts). Fetus is cephalic, reassuring NST. What is the most appropriate management strategy?", "options": ["Diagnose superimposed preeclampsia with severe features and proceed to immediate delivery", "Increase azathioprine dose and schedule induction at 39 weeks if no further worsening", "Administer IV methylprednisolone for suspected lupus nephritis flare and continue pregnancy with close monitoring", "Start magnesium sulfate and attempt blood pressure control; delay delivery until 37 weeks", "Add IV cyclophosphamide for nephritis flare and plan delivery after disease control"], "answer": "C", "answer_index": 2, "explanation": "She has overlapping features but labs favor SLE flare: rising dsDNA, low complement, active urinary sediment with only mild new proteinuria and preserved platelets/LFTs. At 36 weeks, severe preeclampsia would typically show worsening proteinuria and other end-organ features. Pulse steroids for lupus nephritis flare while continuing pregnancy with close monitoring is appropriate; immediate delivery is not mandatory unless maternal or fetal status deteriorates.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette presents a pregnant woman with SLE at 36+1 weeks with hypertension (164/102), headache, visual blurring, edema, worsening proteinuria (2.2 from 1.8), rising creatinine (1.3 from 1.1), and serologic lupus activity (low complement, rising anti-dsDNA, RBC casts). The stem creates diagnostic ambiguity between lupus nephritis flare and superimposed preeclampsia with severe features—both are defensible. Option A (immediate delivery for severe preeclampsia) is defensible: BP ≥160/110 with symptoms (headache, visual changes) meets ACOG severe features criteria at 36 weeks, where delivery is standard. Option C (steroids + expectant management) is defensible if prioritizing lupus flare, but delaying delivery with severe-range BP and neurologic symptoms contradicts preeclampsia management guidelines. The rationale dismisses preeclampsia based on 'preserved platelets/LFTs' and 'only mild new proteinuria,' but severe preeclampsia doesn't require all laboratory abnormalities—severe hypertension with symptoms suffices. Medical accuracy issue: the keyed answer (C) risks maternal harm by continuing pregnancy with uncontrolled severe hypertension and neurologic symptoms. Minimal fix: clarify BP is controllable and symptoms resolve with antihypertensives, or specify no severe features present, making expectant management at 36 weeks defensible.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette presents a pregnant woman with SLE at 36+1 weeks with hypertension (164/102), headache, visual blurring, edema, worsening proteinuria (2.2 from 1.8), rising creatinine (1.3 from 1.1), and serologic lupus activity (low complement, rising anti-dsDNA, RBC casts). The stem creates diagnostic ambiguity between lupus nephritis flare and superimposed preeclampsia with severe features—both are defensible. Option A (immediate delivery for severe preeclampsia) is defensible: BP ≥160/110 with symptoms (headache, visual changes) meets ACOG severe features criteria at 36 weeks, where delivery is standard. Option C (steroids + expectant management) is defensible if prioritizing lupus flare, but delaying delivery with severe-range BP and neurologic symptoms contradicts preeclampsia management guidelines. The rationale dismisses preeclampsia based on 'preserved platelets/LFTs' and 'only mild new proteinuria,' but severe preeclampsia doesn't require all laboratory abnormalities—severe hypertension with symptoms suffices. Medical accuracy issue: the keyed answer (C) risks maternal harm by continuing pregnancy with uncontrolled severe hypertension and neurologic symptoms. Minimal fix: clarify BP is controllable and symptoms resolve with antihypertensives, or specify no severe features present, making expectant management at 36 weeks defensible.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-009", "question": "An intubated 65-year-old woman with severe influenza A pneumonia develops refractory hypoxemia despite lung-protective ventilation (TV 6 mL/kg, PEEP 14 cm H2O, FiO2 0.9) and paralysis. PaO2/FiO2 ratio is 70. She is placed on prone positioning for 16 hours/day with transient improvement but remains PaO2/FiO2 <80. Hemodynamics: MAP 72 mmHg on low-dose norepinephrine, lactate 1.8 mmol/L. No significant comorbidities; BMI 30 kg/m². Family consents to aggressive support. The center has on-site ECMO with experienced team but limited capacity. Which of the following is the most appropriate next step?", "options": ["Increase PEEP to 20 cm H2O and accept permissive hypercapnia before considering ECMO", "Initiate venovenous ECMO now due to refractory severe ARDS despite optimal conventional therapy", "Switch to high-frequency oscillatory ventilation for rescue oxygenation", "Trial inhaled nitric oxide and further proning cycles before deciding on ECMO", "Initiate venoarterial ECMO because of concurrent vasopressor use"], "answer": "B", "answer_index": 1, "explanation": "She has severe ARDS with PaO2/FiO2 <80 despite optimal lung-protective ventilation, high PEEP, paralysis, and proning-meeting criteria for VV-ECMO in an experienced center. Further escalation of ventilator settings or oscillatory ventilation adds risk with limited additional benefit. Low-dose vasopressor does not mandate VA-ECMO; VV-ECMO is appropriate when cardiac function is adequate and shock is not predominant.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 65-year-old woman with severe ARDS (PaO2/FiO2 = 70, then <80) from influenza A pneumonia who has failed all conventional therapies: lung-protective ventilation (TV 6 mL/kg, PEEP 14), neuromuscular blockade, prone positioning (16 hrs/day), and FiO2 0.9. She is hemodynamically stable (MAP 72 on low-dose norepinephrine, lactate 1.8) with family consent and access to experienced ECMO center. Key discriminating findings: refractory hypoxemia despite maximal conventional therapy, adequate hemodynamics, no contraindications. The keyed answer (B, initiate VV-ECMO) is correct per EOLIA trial criteria and current guidelines for severe ARDS (PaO2/FiO2 <80) unresponsive to conventional measures. Option A (further PEEP escalation) risks barotrauma without proven benefit. Option C (HFOV) showed no mortality benefit and potential harm in OSCILLATE trial. Option D delays definitive therapy when ECMO criteria are already met. Option E (VA-ECMO) is incorrect; low-dose vasopressor with normal lactate indicates adequate cardiac function, making VV-ECMO appropriate. No logical flaws or medical inaccuracies. Minimal fix: none needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 65-year-old woman with severe ARDS (PaO2/FiO2 = 70, then <80) from influenza A pneumonia who has failed all conventional therapies: lung-protective ventilation (TV 6 mL/kg, PEEP 14), neuromuscular blockade, prone positioning (16 hrs/day), and FiO2 0.9. She is hemodynamically stable (MAP 72 on low-dose norepinephrine, lactate 1.8) with family consent and access to experienced ECMO center. Key discriminating findings: refractory hypoxemia despite maximal conventional therapy, adequate hemodynamics, no contraindications. The keyed answer (B, initiate VV-ECMO) is correct per EOLIA trial criteria and current guidelines for severe ARDS (PaO2/FiO2 <80) unresponsive to conventional measures. Option A (further PEEP escalation) risks barotrauma without proven benefit. Option C (HFOV) showed no mortality benefit and potential harm in OSCILLATE trial. Option D delays definitive therapy when ECMO criteria are already met. Option E (VA-ECMO) is incorrect; low-dose vasopressor with normal lactate indicates adequate cardiac function, making VV-ECMO appropriate. No logical flaws or medical inaccuracies. Minimal fix: none needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed126-010", "question": "A 10-year-old boy with a history of intermittent asthma presents with 3 weeks of fever, weight loss, night sweats, and progressive joint pains. Exam: non-blanching palpable purpura on lower extremities, mononeuritis multiplex with foot drop, and hypertension (130/86 mmHg). No asthma exacerbation. Labs: ESR 90 mm/hr, CRP 12 mg/dL, creatinine 1.1 mg/dL, urinalysis with 1+ protein and few RBCs, hepatitis B surface antigen positive, high HBV DNA titer, negative ANCA. CT angiography: multiple microaneurysms in mesenteric and renal arteries. What is the most appropriate initial treatment strategy?", "options": ["High-dose corticosteroids plus cyclophosphamide without antiviral therapy", "Start entecavir and delay immunosuppression until HBV viral load is suppressed", "High-dose corticosteroids plus plasma exchange and antiviral therapy", "Rituximab with low-dose steroids and entecavir prophylaxis", "Plasma exchange and entecavir only, avoiding immunosuppression"], "answer": "C", "answer_index": 2, "explanation": "He has HBV-associated polyarteritis nodosa with medium-vessel aneurysms and high viral load. Management requires control of both vasculitis and viral replication: short-course high-dose steroids with plasma exchange and concurrent antiviral therapy is recommended. Prolonged cyclophosphamide without antivirals worsens HBV; antivirals alone are insufficient in active PAN; rituximab is less established in HBV-PAN.", "generator_model": "gpt-5.1-2025-11-13", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The vignette describes a 10-year-old with classic HBV-associated polyarteritis nodosa (PAN): constitutional symptoms, palpable purpura, mononeuritis multiplex, hypertension, positive HBsAg with high HBV DNA, negative ANCA, and characteristic microaneurysms on CT angiography. Key discriminating findings are active HBV infection with high viral load plus severe systemic vasculitis requiring urgent treatment. Option C (high-dose corticosteroids plus plasma exchange and antiviral therapy) correctly addresses both the life-threatening vasculitis and viral replication simultaneously, consistent with current management guidelines for HBV-PAN. Option A risks HBV reactivation with prolonged cyclophosphamide without antivirals. Option B delays necessary immunosuppression in severe active vasculitis. Option D uses rituximab, which lacks established efficacy in HBV-PAN compared to standard therapy. Option E fails to control active vasculitis adequately. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent, reflecting current understanding that HBV-PAN requires concurrent immunosuppression (short-course, not prolonged) with plasma exchange for severe disease plus antiviral therapy. No fix needed; the item is well-constructed and board-appropriate.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The vignette describes a 10-year-old with classic HBV-associated polyarteritis nodosa (PAN): constitutional symptoms, palpable purpura, mononeuritis multiplex, hypertension, positive HBsAg with high HBV DNA, negative ANCA, and characteristic microaneurysms on CT angiography. Key discriminating findings are active HBV infection with high viral load plus severe systemic vasculitis requiring urgent treatment. Option C (high-dose corticosteroids plus plasma exchange and antiviral therapy) correctly addresses both the life-threatening vasculitis and viral replication simultaneously, consistent with current management guidelines for HBV-PAN. Option A risks HBV reactivation with prolonged cyclophosphamide without antivirals. Option B delays necessary immunosuppression in severe active vasculitis. Option D uses rituximab, which lacks established efficacy in HBV-PAN compared to standard therapy. Option E fails to control active vasculitis adequately. The item is logically valid with a single defensible best answer matching the key. Medical accuracy is excellent, reflecting current understanding that HBV-PAN requires concurrent immunosuppression (short-course, not prolonged) with plasma exchange for severe disease plus antiviral therapy. No fix needed; the item is well-constructed and board-appropriate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]